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ABSTRACT: The rapid proliferation of new synthetic cannabinoid receptor agonists (SCRAs) has initiated considerable interest in
the development of so-called “untargeted” screening strategies. One of these new screening technologies involves the activity-based
detection of SCRAs. In this study, we evaluated whether (synthetic) cannabinoid activity can be detected in oral fluid (OF) and, if
so, whether it correlates with SCRA concentrations. OF was collected at several time points in a placebo-controlled JWH-018
administration study. The outcome of the cell-based cannabinoid reporter system, which monitored the cannabinoid receptor
activation, was compared to the quantitative data for JWH-018, obtained via a validated liquid chromatography-tandem mass
spectrometry (LC-MS/MS) method. A total of 175 OF samples were collected and analyzed via both methods. The cannabinoid
reporter assay correctly classified the vast majority of the samples as either negative (<0.25 ng/mL; 74/75 = 99%) or having low
(0.25−1.5 ng/mL; 16/16 = 100% and 1.5−10 ng/mL; 37/41 = 90%), mid (10−100 ng/mL; 23/25 = 92%) or high (>100 ng/mL;
16/18 = 89%) JWH-018 concentrations. Passing−Bablok regression analysis yielded a good linear correlation, with no proportional
difference between both methods (slope 0.97; 95% confidence interval 0.86−1.14) and only a small systematic difference. This is the
first study to demonstrate the applicability of an untargeted, activity-based approach for SCRA detection in OF. Additionally, the
outcome of the cannabinoid reporter assay was compared to the gold standard (LC-MS/MS), showing a good correlation between
both methods, indicating that the cannabinoid reporter assay can be used for an estimation of drug concentrations.
By the end of 2019, 950 novel substances were reported tothe United Nations Office on Drugs and Crime
(UNODC) Early Warning Advisory on new psychoactive
substances (NPS) by governments, laboratories, and partner
organizations. These substances include a broad range of
drugs, such as synthetic cannabinoid receptor agonists
(SCRAs), stimulants, opioids, and benzodiazepines.1 The rise
of NPS has put a huge strain on drug legislations and clinical
and forensic laboratories worldwide in terms of legality and
detectability. Several (new) technologies have been developed
to cope with the problem of detection of NPS. One of these
new screening technologies uses an untargeted approach and
involves the activity-based detection of SCRAs and synthetic
opioids in several biological matrices, including urine, serum,
plasma, and vitreous.2−6 In many cases though, for example, in
the context of driving under the influence of drugs, workplace
testing, or in drug abstinence monitoring, oral fluid (OF) is
used as a matrix for the analysis of drugs of abuse.7−10 OF
offers the advantage that the sampling is noninvasive and that
the parent compounds can be detected in the matrix. This
study is the first to assess whether (synthetic) cannabinoid
activity can be detected in OF. To evaluate the proof-of-
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principle, OF was collected at several time points in a
controlled administration study with a number of subjects (n =
23) using a low dose of a well-known SCRA, JWH-018. The
semiquantitative outcome of the activity-based assay was
compared to the quantitative data for JWH-018 obtained via a
validated liquid chromatography-tandem mass spectrometry
(LC-MS/MS) method.
■ MATERIALS AND METHODS
Chemicals and Reference Standards. The reference
substance JWH-018 and its deuterated internal standard (IS)
JWH-018-d11 were purchased from Cayman Chemical
Company (Ann Arbor, MI, USA) and Lipomed AG
(Arlesheim, Switserland), respectively. Methanol (ULC-
grade) and hexane (HPLC-grade) were purchased from
Biosolve (Valskenswaard, The Netherlands), and ammonium
formate (powder) was obtained from VWR (Leuven,
Belgium). Deionized water was prepared using Arium Comfort
(Sartorius, Belgium). Dulbecco’s modified Eagle’s medium
(GlutaMAX), Opti-MEMI reduced serum medium, penicillin−
streptomycin (5000 IU/mL), and amphotericin B (250 μg/
mL) were purchased from Thermo Fisher Scientific
(Pittsburgh, PA, USA). Fetal bovine serum (FBS) and poly-
D-lysine were supplied by Sigma-Aldrich (Overijse, Belgium).
Biological Samples. Twenty-three healthy cannabis-
experienced participants took part in this placebo-controlled,
crossover study at Maastricht University. Participants inhaled
the smoke of 75 μg JWH-018/kg bodyweight (average 5.5 mg)
or 50 mg Knaster Hemp (placebo, tobacco-replacement herbal
blend, Future Necessities B.V., Sittard, The Netherlands) on
two separate days. JWH-018 powder was heated via a vaporizer
pen (Puffco Plus vaporizer, CA, USA), which reaches
temperatures of approximately 380 °C. Participants inhaled
the vapor in five intakes, according to a strict inhalation
regimen. In case participants did not show a subjective
response within 15 min after administration (i.e., a subjective
high score <3), a booster dose of 50 μg/kg bodyweight was
administered.11 OF samples were obtained using the Intercept
i2 Oral Fluid Collection Device (OraSure Technologies, Inc.,
PA, USA, obtained from Meridian BioScience Europe, Braine-
l’Alleud, Belgium) at several time points (5, 15, 45, 120 min)
after inhalation. After collection, the devices were centrifuged
and stored at −18 °C until analysis of JWH-018, as described
below. For 20 participants, OF samples were collected during
the 2 days. There were also 3 participants for whom only
samples were collected on the day JWH-018 was administered.
The study was approved by the standing Medical Ethics
Committee of Maastricht University and was carried out in
compliance with the current revision of the Declaration of
Helsinki (Fortaleza, 2013) and the International Conference
on Harmonization Guidelines for Good Clinical Practice. A
written informed consent was obtained from all participants.
Standard Solutions, Calibrators, and Quality Control
Samples. The primary stock solution (1 mg/mL) was
prepared by dissolving 5 mg of the JWH-018 standard in 5
mL of methanol and was conserved for 6 months at −20 °C.
Independently prepared solutions were used for the working
solutions to prepare calibrators and quality control samples
(QCs), which were prepared from drug-free OF, diluted 3-fold
with the stabilizing solution in the Intercept i2 Oral Fluid
Collection Device. The primary methanolic working solution
of JWH-018 was prepared just before use at a concentration of
0.333 μg/mL. Two additional methanolic working solutions
were prepared via 1/10 and 1/100 dilution of the primary
working solution. For the calibrators, 12.5−50 μL of the
working solutions were added to 500 μL of the diluted oral
fluid in buffer to obtain a concentration range from 0.25 to 100
ng of JWH-018 per mL in a neat oral fluid. For the QCs,
separate working solutions (with the same concentrations)
were made, and 12.5 or 37.5 μL was added to the diluted oral
fluid to obtain the concentrations of 0.25 (lower limit of
quantification; LLOQ), 0.75 (low), 7.5 (mid), and 75 ng/mL
(high) of JWH-018 in neat oral fluid. The methanolic
deuterated IS stock solution (JWH-018-d11) was prepared at
a concentration of 0.025 μg/mL and conserved for 6 months at
−20 °C.
Sample Preparation. When during collection the volume
adequacy indicator on the Intercept device turns blue, an OF
volume of about 1 mL (n = 77; 95% confidence interval:
0.9635−1.097 mL) has been collected. The pad was inserted
into 2 mL of the stabilizing solution, resulting in a 3-fold
dilution. After centrifugation for 10 min at 3500 rpm, the
diluted OF was collected and stored at −18 °C until analysis.
For LC-MS/MS analysis, 16.7 μL of IS solution was added to a
500 μL aliquot of the diluted OF (to a theoretical
concentration of 2.5 ng/mL in neat OF). Next, 2 mL of
hexane was added, followed by shaking and centrifugation
prior to transfer of the organic phase to a glass tube and
evaporation to dryness under a stream of nitrogen at 40 °C.
The residue was reconstituted in 1 mL of mobile phase A/B
(90/10, v/v) prior to LC-MS/MS analysis.
For the bioassay analysis, another 500 μL aliquot of diluted
OF was processed as described above except that it was not
spiked with IS. The evaporated extract was reconstituted in
100 μL of Opti-MEM I/methanol (50/50, v/v), of which 10
μL was used per well (see Cannabinoid Reporter Assay
section). Calibration standards were prepared from drug-free
OF, diluted 3-fold with the stabilizing solution in the Intercept
device and mixed with methanolic standard solution
containing JWH-018. The final concentrations of the
calibrators were 0.25, 0.5, 1, 2.5, 5, 10, 50, and 100 ng/mL
neat OF for the LC-MS/MS calibration curve and 0.5, 1, 2.5, 5,
10, 50, 100, 500, and 1000 ng/mL neat OF for the bioassay
analysis.
LC-MS/MS Instrumentation and Analytical Condi-
tions. The instrument used was an ACQUITY UPLC system
coupled to a tandem mass spectrometer XEVO TQ MS
(Waters, Milford, MA, USA). After injection of 1 μL of extract,
the analyte was separated at 40 °C on an Acquity UPLC C18
1.7 μm (2.1 mm × 100 mm) column (Waters, Milford, MA,
USA). The mobile phase consisted of water containing 1 mM
ammonium formate (A), and methanol (B). The elution
program with a flow rate of 0.35 mL/min started at 90% B,
increasing for 2 min to 99%, after which it returned to 90% at
minute 3, followed by re-equilibration for 2 min, resulting in a
total run time of 5 min. Electrospray parameters were as
follows: cone gas flow, 150 L/h; nebulizer gas flow, 7 bar;
desolvation temperature, 650 °C; capillary voltage, 1kv; source
temperature, 150 °C. The MS/MS was operated in a multiple
reaction monitoring mode (MRM) with two transitions for the
analyte and the internal standard. The transitions were (m/z,
cone and collision energy in parentheses, quantifier under-
lined): JWH-018 342.1 → 127 (40,40), 342.1 → 154.9
(40,30); JWH-018-d11 353.2 → 127.2 (20,40), 353.2 → 155.2
(20,20). Data evaluation was performed using the Targetlynx
Software (Waters, Milford, MA, USA).
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Method Validation. In a previous JWH-018 adminis-
tration study, it was already shown that the metabolites of
JWH-018 were not present in OF (<limit of detection of 0.05
ng/mL);9 therefore, these were not included in the LC-MS/
MS method. The method was validated according to the
protocol described by Wille et al.12,13 In each analytical run, a
control blank (i.e., sample prepared from a blank matrix that
does not contain the IS), a zero sample (i.e., sample prepared
from a blank matrix that includes the IS), and QC samples
were included. Selectivity was assessed by analyzing 10 buffer/
oral fluid mixtures using blank oral samples from 10 different
individuals and two zero samples. The absence of interfering
components was accepted if the response at the retention time
of JWH-018 was less than 20% of the LLOQ for JWH-018.
Carry-over was assessed by injection of a blank solvent after 3.5
times the highest calibrator (n = 10) using the same acceptance
criteria as for selectivity. For evaluation of linearity, calibration
curves with eight levels (0.25−100 ng/mL) using internal
standardization were evaluated (in duplicate on five different
days). Precision and bias of the method were evaluated over
the linear dynamic range at four different concentration levels,
i.e., the lower limit of quantification (LLOQ; 0.25 ng/mL), low
level (0.75 ng/mL), medium level (7.5 ng/mL), and high level
(75 ng/mL). Each concentration was analyzed in duplicate on
five separate days. Accuracy and precision were considered
acceptable if %RSD and %bias were within 15% and 20% for
the LLOQ.14,15 The evaluation of extraction efficiency (EE)
and matrix effects (ME) was conducted according to the
method published by Matuszewski et al.16 at low (0.75 ng/mL
JWH-018) and high (75 ng/mL JWH-018) concentrations (n
= 10). For the evaluation of ME, analyte-free diluted oral fluid
from 10 individual donors was used. Extracts (i.e., the 2 mL
supernatants mentioned in the Sample Preparation section)
prepared from blank diluted oral fluid were spiked at
concentrations corresponding to low QC and high QC level
(B). Neat solvent (methanol−ammonium formate (1 mM) in
water, 90:10, v/v) was spiked at the same concentration levels
(A). Absolute ME was calculated by dividing the peak area of
(B) by the peak area obtained from (A), multiplied with 100%
(n = 10). IS-compensated ME was calculated similarly by
taking into account the IS peak area for (A) and (B). For the
evaluation of EE, diluted oral fluid was spiked at low QC and
high QC levels before (C) and after (B) extraction. The EE
was determined by dividing the peak area ratio of (C) by the
peak area ratio of (B), multiplied with 100% (n = 10). The
recovery of JWH-018 from the oral fluid device was also
evaluated at low, medium, and high levels (n = 6). Analyte
stability determinations comprised an assessment of the
freeze/thaw cycle stability (three cycles) and long-term
stability (5 months at −20 °C) of the diluted oral fluid and
the processed sample stability of the obtained extracts
(autosampler stability 72 h at 4 °C). These were performed
at low and high levels (same concentrations as for the EE and
ME) in sextuplicate.
Cannabinoid Reporter Assay. A live cell-based reporter
assay that monitors protein−protein interactions via the
NanoLuc Binary Technology was used to assess the
cannabinoid activity in the samples. Here, the receptor
activation is evaluated via the interaction between a cytosolic
truncated β-arrestin 2 (βarr2) protein and the cannabinoid
receptor 1 (CB1).3 Both βarr2 and CB1 are fused to an
inactive part of nanoluciferase. Upon CB1 activation, βarr2 is
recruited to the receptor, allowing interaction of the
complementary nanoluciferase subunits, yielding a functional
enzyme that generates a bioluminescent signal in the presence
of the substrate furimazine. The original human embryonic
kidney (HEK) T293 cell line was provided by Prof. O. De
Wever (Laboratory of Experimental Cancer Research, Ghent
University Hospital, Belgium) and was modified to stably
express the cannabinoid reporter system.2 The stability of the
cell line (i.e., the expression levels of fusion proteins) was
monitored by flow cytometric analysis.
The cells were routinely maintained at 37 °C and 5% CO2,
under a humidified atmosphere in Dulbecco’s modified Eagle’s
medium (GlutaMAX) supplemented with 10% heat-inacti-
vated FBS, 100 IU/mL penicillin, 100 mg/L streptomycin, and
0.25 mg/L amphotericin B. For experiments, cells were seeded
on poly-D-lysine coated 96-well plates at 5 × 104 cells/well and
incubated overnight. The cells were washed twice with Opti-
MEM I reduced serum medium to remove any remaining FBS,
and 100 μL Opti-MEM I was added. The Nano-Glo live cell
reagent (Promega, Madison, WI, USA), a nonlytic detection
reagent containing the cell permeable furimazine substrate, was
prepared by 20-fold dilution of the Nano-Glo live cell substrate
using Nano-Glo LCS dilution buffer, and 25 μL was added to
each well. Subsequently, the plate was placed into a TriStar2
LB942 multimode microplate reader (Berthold Technologies
GmbH & Co., Germany). Luminescence was monitored
during the equilibration period until the signal stabilized (15
min). We added 10 μL of extract (see Sample Preparation
section) per well. The luminescence was continuously detected
for 120 min. For each 96-well plate, a calibration curve (0.5−
1000 ng/mL) was used. Also, solvent controls were analyzed
with all experiments.
Curve fitting of the calibration curves and statistics were
performed using GraphPad Prism software (San Diego, CA,
USA) and Medcalc software (Ostend, Belgium). The data are
represented as mean areas under the curve (AUC) ± standard
deviation (SD) with two replicates for each data point. Curve
fitting of calibration curves was done via nonlinear regression
(four parameter logistic fit; 4PL). This allowed us to calculate
the concentration of JWH-018 in the participant samples using
the following formulas:
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where a is the minimal value, b the hill’s slope, c the point of
inflection, d the maximal value, x the concentration, and y the
AUC.
For those samples with AUC values below the minimal (a)
or above the maximal (d) values, no numerical value could be
assigned via the bioassay. These were classified as either too
low or too high to be calculated by the bioassay. All samples
above a certain threshold were considered positive and were
assigned a semiquantitative value for JWH-018. This threshold
can be determined via a receiver operating characteristic
(ROC) curve or can be calculated based on the standard
deviation of the response and the slope17 by using a specific
calibration curve in the lower range (0.5−10 ng/mL) using the
following formula
S
Threshold
3.3σ=
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where σ is the standard deviation of the response (residual
standard deviation of a regression line), and S is the slope of
the calibration curve.
■ RESULTS AND DISCUSSION
LC-MS/MS Method Validation. For the selectivity, no
interfering components (<20% of LLOQ) were found at the
retention time of JWH-018. There was no carry-over observed
in the blanks following the injection of 3.5 times the highest
calibrator (350 ng/mL). The calibration data were hetero-
scedastic. For the quantification of JWH-018 in diluted oral
fluid, a linear model with a weighing factor of 1/x2 was the best
fitting model based upon the procedure for the selection and
validation of a calibration model by Desharnais et al.18 The
selected regression model met the preset acceptance criteria
(%RE < 15% for the calibrators and <20% for the LLOQ). The
accuracy, intraday precision, and total precision for QCs,
analyzed in duplicate on five different days, fulfilled the
predefined criteria (%bias and %RSD < 15%, 20% for LLOQ),
as shown in Table 1.
The absolute ME and IS-corrected ME approximated 100%
for both the low QC and high QC levels, indicating no
significant enhancement or suppression of ionization. The
relative ME fulfilled the predetermined acceptance criteria
(<15%), with a maximum value of 6.66% (Table 2). The EE
values (mean ± SD) obtained were 80.9 ± 10.9% and 82.9 ±
9.9% for low and high QC samples, respectively. The actual
recovery of JWH-018 from the oral fluid device (Intercept i2
collector) was low, with rates of 29.5 ± 8.1%, 26.5 ± 8.1%, and
27.4 ± 11.6% at low, medium, and high levels, respectively,
indicating adsorption by the collection pad. This problem is
well-known, especially for lipophilic compounds19−23 and has
been observed with several devices (Quantisal, Drag̈er DCD
5000).24−26 The IS, only added after the pad has been
removed from the diluted oral fluid, does not compensate for
this loss, implying there is a substantial underestimation of
actual OF concentrations. Although this shortens the detection
time, this was not an issue in our study, as we could still
compare the semiquantitative outcome of the cannabinoid
reporter assay with the quantitative data for JWH-018. For the
purpose of this study (comparison of the cannabinoid reporter
assay with LC-MS/MS), it was not possible to add IS already
at an earlier stage, as also the IS will have cannabinoid activity.
For the diluted oral fluid samples, the freeze/thaw (three
cycles) and long-term stability (5 months at −20 °C) data
remained within 10% of the control (7.25%/7.73% and 9.26%/
9.82% for low/high levels, respectively). The processed sample
stability (72 h at 4 °C) samples showed less than 15% from the
initial amount confirming stability of extracts in the
autosampler (−14.8%/3.08% for low/high levels).
OF Sampling. In this study, JWH-018 was administered by
inhalation via vaping, and OF was collected at several time
points using the Intercept i2 collector. For detection of JWH-
018 in OF, the contamination of the oral cavity is very
important as it was reported that SCRAs are only transferred at
a very low rate from the bloodstream into the OF (and vice
versa).9 Therefore, OF is well suited for the detection of recent
SCRA use.25 The level of oral cavity contamination is highly
variable between individuals,25 as also observed in this study,
where the maximal concentrations varied from 6.10 to >100
ng/mL JWH-018. The maximal concentrations that were
found in this study (median >100 ng/mL) were higher than
those in a similar JWH-018 administration study (median 25.7
ng/mL).9 This may be due to the higher dose inhaled (average
5.5 mg JWH-018 versus 3 mg JWH-018) and/or due to the
fact that in this study a vaping system was used to inhale the
drug instead of a “crack pipe”. The former was much more
convenient to use for the participants, which might contribute
to the higher concentrations found.
Cannabinoid Reporter Assay Model. The calibration
curves (0.5−1000 ng/mL, prepared in matrix) obtained via the
cannabinoid reporter assay are sigmoidal. Curve fitting was
done via nonlinear regression (four parameter logistic fit;
4PL). The study participant samples were analyzed in five
different runs alongside a calibration curve. Statistical analysis
did not reveal any significant difference between the hill’s
slopes (b) and the points of inflection (c) of the calibration
curves from the different runs (Figure 1A).
(Semi)quantification of OF Samples. A total of 175 OF
samples were collected and analyzed via both the LC-MS/MS
method and the cannabinoid reporter assay (Table 3). Via the
LC-MS/MS analysis, 75 were below the LLOQ of 0.25 ng/mL,
whereas 18 were above the ULOQ (upper limit of
quantification) of 100 ng/mL JWH-018. The large fraction
of samples below the LLOQ originated from the samples taken
on placebo days. From the 76 (= 19 × 4) samples taken on the
placebo days, 71 were, as expected, below the LLOQ, although
in five cases low levels of JWH-018 (0.32−2.63 ng/mL) were
found. In four of these cases, it was the first sample (5 min
after inhalation) which showed this slight positivity, which
could be explained if the mouth piece or the chamber of the
vaping device was contaminated from previous use. For the
actual comparison of the bioassay results with those from the
LC-MS/MS assay, this apparent contamination issue did not
matter.
On the basis of the 4PL model of the calibration curve, the
JWH-018 concentrations from the participant samples could
be calculated from their AUC values. All samples above a
certain threshold (1.50 ng/mL) were considered positive and
were assigned a semiquantitative value for JWH-018. This
threshold was established using a receiver operating character-
istic (ROC) curve to choose the most appropriate “cutoff”, i.e.,
showing a combination of the best sensitivity and specificity
Table 1. Accuracy (%bias), Intraday, and Total Precision (%
RSD) Data for QC Samples Prepared at Four Concentration
Levels for Diluted Oral Fluid Samples (n = 5 × 2)
QC
Accuracy
(% bias)
Intraday precision
(% RSD)
Total precision
(% RSD)
LLOQ 7.35 6.63 9.11
Low 1.72 4.96 8.74
Medium −1.84 5.80 6.99
High 0.82 4.70 6.55
Table 2. Absolute and Relative Matrix Effect at Low QC and
High QC Levels Made from Spiked Diluted Oral Fluid from
10 Different Donors (n = 10)
Absolute matrix effect
(mean %)
Relative matrix effect
(% RSD)
QC without IS with IS without IS with IS
Low 102 104 2.49 6.66
High 99 103 6.16 4.30
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(Figure 1B). This threshold closely matches the theoretical
threshold of 1.69 ng/mL, which can be calculated based on the
standard deviation of the response and the slope by using a
specific calibration curve,17 in the lower range, run along with
participants’ samples (0.5−10 ng/mL, n = 5). When scoring
samples being JWH-018 positive or negative on the basis of the
quantitative LC-MS/MS results with 1.50 ng/mL as threshold,
the data yielded an overall sensitivity and specificity of 82%
(82/100) and 99% (74/75), respectively. This does not take
into account the fact that the LLOQ of the LC-MS/MS
method (0.25 ng/mL) is lower than the bioassay’s threshold of
1.50 ng/mL. Overall, the bioassay scored 92 samples below the
threshold of 1.50 ng/mL, 67 samples between 1.50−100 ng/
mL, and 16 samples above 100 ng/mL (Table 3).
The cannabinoid reporter assay scored all 75 samples below
the LLOQ of the LC-MS/MS method either below the
bioassay’s threshold (1.50 ng/mL; n = 74) or in the lower
concentration range of the bioassay (1.71 ng/mL; n = 1). The
16 samples with a concentration between the LLOQ of the
LC-MS/MS (0.25 ng/mL) and the threshold of the bioassay
(1.50 ng/mL) were all scored as being below 1.50 ng/mL.
From the 41 samples with concentrations between 1.50−10
ng/mL in the LC-MS/MS method, 90% (37/41) were also
assigned as such in the cannabinoid reporter assay (Table 3).
Within this set, two samples were scored higher in the
cannabinoid reporter assay (17.42 and 13.3 ng/mL versus 8.89
and 7.48 ng/mL). Two other samples were scored below the
bioassay’s threshold of 1.50 ng/mL JWH-018, although the
corresponding LC-MS/MS concentrations were 2.29 and 3.08
ng/mL. Twenty-three of the 25 samples (92%) that were
measured between 10−100 ng/mL via the LC-MS/MS
method were also calculated between that range in the
bioassay. The two samples that were divergent had a
concentration of 14.15 and 19.01 ng/mL in the LC-MS/MS
method, while values of, respectively, 7.54 and 5.88 ng/mL
were derived from the cannabinoid reporter assay. Sixteen of
the 18 samples (89%) above the ULOQ of the LC-MS/MS
method were also scored greater than 100 ng/mL in the
cannabinoid reporter assay. The two remaining samples were
assigned concentrations of 81.1 and 86.5 ng/mL in the
bioassay, still matching the concentrations found via LC-MS/
MS (semiquantitative: 109 and 120 ng/mL) quite well.
Overall, these data show that the cannabinoid reporter assay
allows a reasonably good estimate of the JWH-018
concentration, both at low and high concentrations. Next, we
looked at the 64 samples that were quantifiable via both the
LC-MS/MS and the cannabinoid reporter assay (bold in Table
3). The differences between measured concentrations in both
methods can readily be deduced from Figure 2, depicting the
Passing−Bablok regression analysis, yielding a good linear
correlation (y = 0.9745x + 0.8244). The 95% confidence
interval of the slope contains 1 (0.8573−1.1415), indicating
that there was no proportional difference between the two
methods, although there is a slight systematic difference as the
95% confidence interval of the intercept does not contain 0
(0.3747−1.1866).
Figure 1. (A) Representation of the five different calibration curves
(normalized to 100%), showing no significant difference between the
different runs. (B) Receiver operating characteristic (ROC) curve to
choose the most appropriate threshold for the cannabinoid reporter
assay (= 1.50 ng/mL).
Table 3. Overview of 175 Oral Fluid Samples Analysed via Both the LC-MS/MS Method and Cannabinoid Reporter Assaya
aGray boxes indicate correctly scored samples by the cannabinoid reporter assay. Bold numbers refer to the data used for the Passing−Bablok
analysis (Figure 2).
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Figure 3 shows the absolute differences between the JWH-
018 concentrations determined via the cannabinoid reporter
assay and LC-MS/MS. There is an overall mean difference of
0.4 ng/mL JWH-018 between both methods. As can be seen,
the absolute difference between the two methods is limited at
low concentrations (<10 ng/mL). At higher concentrations
(10−100 ng/mL), these differences are more pronounced.
This can be explained by the semiquantitative nature of the
cannabinoid reporter assay. The concentration of JWH-018 is
calculated via the 4PL fit, using a sigmoidal curve with a
logarithmic scale in the x-axis (Figure 1A). A small deviation in
the AUC (y-axis) can result in a large difference in the
calculated concentration (x-axis), especially at higher concen-
trations. Additionally, one has to take into account that the
cannabinoid reporter assay does not allow the use of an IS to
cope with any variation during sample preparation. So,
although the absolute deviation might seem pronounced
(especially at higher concentrations (10−100 ng/mL)), the
bioassay does allow for providing a semiquantitative estimate
of the JWH-018 concentration in a sample.
■ CONCLUSION
Although the number of new SCRAs has gone down in the last
couple of years, they still dominate (together with cathinones)
the number of seizures, indicating they remain drugs to be
reckoned with.1 The present study is the first to evaluate the
application of an untargeted, activity-based approach for the
detection of SCRAs in OF. It is also the first time that, using
authentic samples, the potential of the bioassay to deliver
semiquantitative results is demonstrated. The bioassay
correctly classified the vast majority of the samples as either
negative (<0.25 ng/mL; 74/75 = 99%), or having low (0.25−
1.5 ng/mL; 16/16 = 100% and 1.5−10 ng/mL; 37/41 = 90%),
mid (10−100 ng/mL; 23/25 = 92%), or high (>100 ng/mL;
16/18 = 89%) JWH-018 concentrations. This indicates that,
besides urine, vitreous, plasma, serum, or blood, the activity-
based cannabinoid reporter assay can also be used to screen
OF for cannabinoid activity. Moreover, our results indicate
that activity-based testing can not only be used to point out
whether a sample is positive or not but also to get an estimate
of drug concentrations. In the case presented here, JWH-018
was the sole analyte present at relevant concentrations in the
evaluated matrix. In the future, it will be relevant to evaluate
whether also the activity of a combination of analytes (main
compounds and metabolites) can accurately be predicted. To
achieve this, a proper “activity threshold” (corresponding to a
“concentration threshold” of a reference compound) should be
defined. This could be done by running a set of calibration
lines (of e.g. JWH-018) at low concentrations and using the
slope and standard deviation of the response to calculate this
threshold. This would lend further support to the concept of
“activity equivalents”,27 via which the combined activity of
analytes present in a biological matrix can be used to get a
better idea about the degree of intoxication. Although not
within the scope of this study, we anticipate that also OF in
which THC is present at relatively high concentrations may
yield a positive response in the activity-based assay (as THC is
only a relatively weak CB1 agonist we anticipate only a weak
response, even at relatively high concentrations).28 However,
we do not envisage the use of activity-based screening to
routinely detect the presence of THC in OF. Conventional
approaches, either antibody-based screening or routine GC- or
LC-MS/MS procedures, typically offer sufficient specificity and
superior sensitivity for this purpose. However, as the higher
penetration of these conventional tests in, for example,
roadside testing may paradoxically cause an incentive to use
SCRAs, which are typically not tested for in this context,
screening OF for cannabinoid activity, as a complement, may
allow closing this loophole.
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